-
Something wrong with this record ?
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
A. Rizzo, S. Buti, P. Giannatempo, S. Salah, J. Molina-Cerrillo, F. Massari, RM. Kopp, O. Fiala, L. Galli, ZW. Myint, D. Tural, A. Soares, R. Pichler, A. Mennitto, H. Abahssain, F. Calabrò, FSM. Monteiro, A. Albano, V. Mollica, GC. Giudice, H....
Language English Country Netherlands
Document type Journal Article, Multicenter Study
NLK
ProQuest Central
from 1998-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1998-01-01 to 1 year ago
- MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized * therapeutic use MeSH
- Carcinoma, Transitional Cell * drug therapy pathology mortality secondary MeSH
- Middle Aged MeSH
- Humans MeSH
- Antineoplastic Agents, Immunological therapeutic use MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Urologic Neoplasms drug therapy pathology mortality MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
Upper tract urothelial carcinoma (UTUC) accounts for the 5-10% of all urothelial carcinomas (UCs). In this analysis, we reported the real-world data from the ARON-2 study (NCT05290038) on the efficacy of pembrolizumab in patients with UTUC who recurred or progressed after platinum-based chemotherapy. Medical records of patients with metastatic UTUC treated with pembrolizumab as second-line therapy were reviewed from 34 institutions in 14 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 235 patients were included in our analysis. Median OS was 8.6 months (95% CI 6.6-12.1), the 1 year OS rate was 43% while the 2 years OS rate 29%. The median PFS was 5.1 months (95% CI 3.9-6.9); 46% of patients were alive at 6 months, 34% at 12 months and 25% at 24 months. According to RECIST 1.1, 18 patients (8%) experienced complete response (CR), 57 (24%) partial response (PR), 44 (19%) stable disease (SD), and 116 (49%) progressive disease (PD), with an ORR of 32%. Our study confirms the effectiveness of pembrolizumab in patients pretreated with a platinum-based combination, irrespective of their sensitivity to the first-line treatment and of their histology. In addition, we emphasized the limited benefit of the treatment with pembrolizumab in patients with hepatic metastases and poor ECOG performance status.
1 R C C S Istituto Tumori Giovanni Paolo 2 Viale Orazio Flacco 65 70124 Bari Italy
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Centro Paulista de Oncologia Grupo Oncoclínicas Hospital Albert Einstein São Paulo SP Brazil
Clinical Oncology Sociedad de Oncología y Hematología del Cesar Valledupar Colombia
Department of Medical and Surgical Sciences University of Bologna Bologna Italy
Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain
Department of Medical Oncology IRCCS San Raffaele Hospital Milan Italy
Department of Medical Oncology King Hussein Cancer Center Amman Jordan
Department of Medical Oncology Maggiore della Carità University Hospital Novara Italy
Department of Urology Medical University of Innsbruck Anichstrasse 35 6020 Innsbruck Austria
Department of Urology Saitama Medical Center Saitama Medical University Saitama Japan
Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil
Latin American Cooperative Oncology Group LACOG Porto Alegre RS Brazil
Markey Cancer Center University of Kentucky Lexington KY USA
Medical Oncology 1 IRCCS Regina Elena National Cancer Institute Rome Italy
Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italy
Oncology and Hematology Department Hospital Santa Lucia SHLS 716 Cj C Brasília DF 70390 700 Brazil
Oncology Unit 2 University Hospital of Pisa 56126 Pisa Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004068
- 003
- CZ-PrNML
- 005
- 20250206105115.0
- 007
- ta
- 008
- 250121s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10585-024-10296-0 $2 doi
- 035 __
- $a (PubMed)38850317
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Rizzo, Alessandro $u I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy. rizzo.alessandro179@gmail.com
- 245 10
- $a Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project / $c A. Rizzo, S. Buti, P. Giannatempo, S. Salah, J. Molina-Cerrillo, F. Massari, RM. Kopp, O. Fiala, L. Galli, ZW. Myint, D. Tural, A. Soares, R. Pichler, A. Mennitto, H. Abahssain, F. Calabrò, FSM. Monteiro, A. Albano, V. Mollica, GC. Giudice, H. Takeshita, M. Santoni, ARON Working Group
- 520 9_
- $a Upper tract urothelial carcinoma (UTUC) accounts for the 5-10% of all urothelial carcinomas (UCs). In this analysis, we reported the real-world data from the ARON-2 study (NCT05290038) on the efficacy of pembrolizumab in patients with UTUC who recurred or progressed after platinum-based chemotherapy. Medical records of patients with metastatic UTUC treated with pembrolizumab as second-line therapy were reviewed from 34 institutions in 14 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 235 patients were included in our analysis. Median OS was 8.6 months (95% CI 6.6-12.1), the 1 year OS rate was 43% while the 2 years OS rate 29%. The median PFS was 5.1 months (95% CI 3.9-6.9); 46% of patients were alive at 6 months, 34% at 12 months and 25% at 24 months. According to RECIST 1.1, 18 patients (8%) experienced complete response (CR), 57 (24%) partial response (PR), 44 (19%) stable disease (SD), and 116 (49%) progressive disease (PD), with an ORR of 32%. Our study confirms the effectiveness of pembrolizumab in patients pretreated with a platinum-based combination, irrespective of their sensitivity to the first-line treatment and of their histology. In addition, we emphasized the limited benefit of the treatment with pembrolizumab in patients with hepatic metastases and poor ECOG performance status.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 12
- $a karcinom z přechodných buněk $x farmakoterapie $x patologie $x mortalita $x sekundární $7 D002295
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
- 650 _2
- $a urologické nádory $x farmakoterapie $x patologie $x mortalita $7 D014571
- 650 _2
- $a dospělí $7 D000328
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Buti, Sebastiano $u Medical Oncology Unit, Department of Medicine and Surgery, University Hospital of Parma, University of Parma, Parma, Italy
- 700 1_
- $a Giannatempo, Patrizia $u Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy
- 700 1_
- $a Salah, Samer $u Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan
- 700 1_
- $a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Massari, Francesco $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy $u Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
- 700 1_
- $a Kopp, Ray Manneh $u Clinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia
- 700 1_
- $a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Galli, Luca $u Oncology Unit 2, University Hospital of Pisa, 56126, Pisa, Italy
- 700 1_
- $a Myint, Zin W $u Markey Cancer Center, University of Kentucky, Lexington, KY, USA
- 700 1_
- $a Tural, Deniz $u Department of Medical Oncology, Bakirköy Dr. SadiKonuk Training and Research Hospital, Tevfik Saglam St. No: 11, BakirkoyZuhuratbaba District, Istanbul, Turkey
- 700 1_
- $a Soares, Andrey $u Latin American Cooperative Oncology Group-LACOG, Porto Alegre, RS, Brazil $u Centro Paulista de Oncologia/Grupo Oncoclínicas, Hospital Albert Einstein, São Paulo, SP, Brazil
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
- 700 1_
- $a Mennitto, Alessia $u Department of Medical Oncology, "Maggiore della Carità" University Hospital, Novara, Italy
- 700 1_
- $a Abahssain, Halima $u Medical Oncology Unit, Medicine and Pharmacy Faculty, National Institute of Oncology, Mohamed V University, Rabat, Morocco
- 700 1_
- $a Calabrò, Fabio $u Medical Oncology 1-IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 700 1_
- $a Monteiro, Fernando Sabino M $u Latin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil $u Oncology and Hematology Department, Hospital Santa Lucia, SHLS 716 Cj. C, Brasília, DF, 70390-700, Brazil
- 700 1_
- $a Albano, Anna $u I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy
- 700 1_
- $a Mollica, Veronica $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy $u Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
- 700 1_
- $a Giudice, Giulia Claire $u Medical Oncology Unit, Department of Medicine and Surgery, University Hospital of Parma, University of Parma, Parma, Italy
- 700 1_
- $a Takeshita, Hideki $u Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
- 700 1_
- $a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy
- 710 2_
- $a ARON Working Group
- 773 0_
- $w MED00007574 $t Clinical & experimental metastasis $x 1573-7276 $g Roč. 41, č. 5 (2024), s. 655-665
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38850317 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206105110 $b ABA008
- 999 __
- $a ok $b bmc $g 2263676 $s 1240075
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 41 $c 5 $d 655-665 $e 20240608 $i 1573-7276 $m Clinical & experimental metastasis $n Clin Exp Metastasis $x MED00007574
- LZP __
- $a Pubmed-20250121
